TURKU, FINLAND--(Marketwire - June 18, 2008) - Top-line data from the first-in-man study with Biotie's fully human VAP-1 monoclonal antibody BTT-1023 have become available. The study was conducted in a clinical pharmacology unit in the United Kingdom and investigated the safety, tolerability and pharmacokinetic characteristics of single intravenous doses of BTT-1023 in healthy volunteer subjects.
